alendronate has been researched along with raloxifene hydrochloride in 173 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (7.51) | 18.2507 |
| 2000's | 100 (57.80) | 29.6817 |
| 2010's | 50 (28.90) | 24.3611 |
| 2020's | 10 (5.78) | 2.80 |
| Authors | Studies |
|---|---|
| Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE | 1 |
| Bemis, K; Bryant, HU; Burr, DB; Helterbrand, J; Higgs, R; Iversen, P; Owan, I; Sato, M; Smietana, F; Takano, Y; Turner, CH | 1 |
| Zaidi, M | 1 |
| Meier, CA | 1 |
| Tonino, RP | 1 |
| Robb-Nicholson, C | 1 |
| Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB | 1 |
| Ullom-Minnich, P | 1 |
| Kleerekoper, M | 2 |
| Dunlop, MB; Lane, NE | 1 |
| Chapman, B | 1 |
| Black, D; Blackwell, T; Browner, W; Cummings, SR; Eckert, S; Marcus, R; Palermo, L; Pearson, J; Wallace, R | 1 |
| Baran, DT | 2 |
| Eisman, JA; Sambrook, PN | 1 |
| Einhorn, TA | 1 |
| Delmas, PD | 1 |
| Mincey, BA; Moraghan, TJ; Perez, EA | 1 |
| Green, SS; Milott, JL; Schapira, MM | 1 |
| Halbekath, J | 1 |
| Dijkmans, BA; Lems, WF | 1 |
| Chapurlat, R; Delmas, PD | 1 |
| Compston, JE | 1 |
| Schein, JR; Sewell, K | 1 |
| Moore, HC | 1 |
| Lenchik, L; Watts, NB | 1 |
| Canfield, G | 1 |
| Slagle, MA | 1 |
| McClung, B; McClung, M | 1 |
| Crandall, C | 1 |
| Kruse, HP | 1 |
| Bilezikian, JP; Ettinger, B | 1 |
| Johnell, O; Lu, Y; Need, AG; Reginster, JY; Scheele, WH; Seeman, E | 1 |
| Grady, D | 1 |
| Hayashi, Y | 1 |
| Ishii, J | 1 |
| Välimäki, MJ | 1 |
| Akiyama, T; Cao, Y; Komatsubara, S; Ma, L; Mashiba, T; Miyamoto, K; Mori, S; Norimatsu, H; Sato, M; Shi, L; Westmore, MS | 1 |
| Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Broy, SB; Derosa, AM; Harrington, JT; Licata, AA; Shewmon, DA | 1 |
| Begerow, B; Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Bartl, R | 2 |
| Bryant, HU; Cole, HW; Hoover, J; Jee, WS; Ma, YL; Sato, M; Schmidt, A; Yao, W; Zeng, Q | 1 |
| Begerow, B; Minne, HW; Pfeifer, M | 1 |
| Martens, MG | 1 |
| Ettinger, B; Grove, MR; Hammond, CS; Hebert, GM; Moncur, MM; Pressman, AR; Ray, GT; Tosteson, AN | 1 |
| Ish-Shalom, S; Segal, E; Tamir, A | 1 |
| Kessenich, C | 1 |
| Hatzigeorgiou, C; Jackson, JL; Tofferi, JK; Wei, GS | 1 |
| Acebes, JC; Graña, J; Herrero-Beaumont, G; Marín, F; Miguélez, R; Sacristán, J; Torrijos, A; Turbí, C | 1 |
| Ferrer-Barriendos, J; Gaines, K; Geusens, P; Melton, ME; Ribot, C; Sambrook, PN; Solimano, JA; Verbruggen, N | 1 |
| Krieg, MA; Lamy, O | 1 |
| Crans, G; Ettinger, B; Pavo, I; San Martin, J | 1 |
| Alenfeld, F; Boivin, G; Feyen, JH; Lakatos, P; Stepan, JJ | 1 |
| Zizic, TM | 1 |
| Keller, MI | 1 |
| Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A | 1 |
| Hagino, H | 2 |
| Falbo, A; Lombardi, G; Manguso, F; Mastrantonio, P; Nunziata, V; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F | 1 |
| Hosking, DJ; Pande, I | 2 |
| Hetzell, CB | 1 |
| Brewer, N; Davis, S; De Nigris, E; Jones, ML; Oakley, J; Stevenson, M | 1 |
| Adachi, JD; Adami, S; Kulkarni, PM; Stock, JL; Wong, M | 1 |
| Ambrose, EM; Bryant, HU; Chen, P; Dow, ER; Frolik, CA; Halladay, DL; Helvering, LM; Huang, S; Kulkarni, NH; Lawrence, F; Liu, R; Ma, YL; Miles, RR; Onyia, JE; Sato, M; Wei, T | 1 |
| Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB | 1 |
| Basson, BR; Michalská, D; Pavo, I; Stepan, JJ | 1 |
| Reginster, JY; Sarlet, N | 1 |
| Takada, J | 1 |
| de Vernejoul, MC | 1 |
| Baris, N; Gol, M; Guneri, S; Posaci, C | 1 |
| Hochberg, MC; Rizzoli, R | 1 |
| Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA | 1 |
| Adachi, J; Blackhouse, G; Goeree, R | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Iori, N; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Sinigaglia, L | 1 |
| Barna, A; Bourgoin, M; Briot, K; Chapurlat, R; Christin-Maitre, S; Cortet, B; Costagliola, D; Diebolt, V; Dumarcet, N; Lacoin, F; Letombe, B; Nouyrigat, E; Oberlin, F; Orcel, P; Ravaud, P; Roux, C; Seret, P; Thomas, T; Veyries, ML; Vogel, JY; Yoldjian, I | 1 |
| Allen, MR; Burr, DB; Follet, H; Khurana, M; Sato, M | 1 |
| Cauley, JA; Gaich, CL; Kendler, D; Kulkarni, PM; Lewiecki, EM; Lorraine, J; Plouffe, L; Qu, Y; Recker, RR; Recknor, CP; Rooney, TW; Stock, JL; Utian, WH; Wong, M | 1 |
| Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D | 1 |
| Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH | 1 |
| Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L | 1 |
| Akçay, A; Bavbek, N; Inegöl, I; Kanbay, M; Turgut, FH; Uz, E; Yanik, B; Yanik, T | 1 |
| Sugimoto, T | 1 |
| Miki, T | 1 |
| Byrjalsen, I; Christiansen, C; Karsdal, MA; Leeming, DJ; Qvist, P | 1 |
| Rizzoli, R | 1 |
| Christodoulakos, GE; Marín, F; Mellström, D; Nickelsen, T; Pavo, I; Petto, H; Ringe, JD | 1 |
| Gowda, S; Mahaseth, HC; Prabhu, H; Shah, BK; Vieira, J | 1 |
| Buckwalter, JG; Geiger, AM; Handler, J; Howes, J; Lehmer, RR; Parsons, TD | 1 |
| Deswaef, A; Fabri, V; Mertens, R; Rabenda, V; Reginster, JY; Sumkay, F; Vannecke, C; Vanoverloop, J; Verpooten, GA | 1 |
| Allen, MR; Burr, DB; Delmas, PD; Gineyts, E; Leeming, DJ | 1 |
| Eiken, PA | 1 |
| Cosman, F; Glass, EV; Krege, JH; Recknor, CP; Wermers, RA; Xie, L | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Silvestri, S; Sinigaglia, L | 1 |
| Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M | 1 |
| Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T | 1 |
| Abrahamsen, B; Eiken, P; Roerholt, C | 1 |
| Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L | 1 |
| Altavilla, D; Antoci, S; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Granese, R; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F | 1 |
| Verhaar, HJ | 1 |
| Stepan, JJ; Zikan, V | 1 |
| Ito, M | 1 |
| Cosman, F; Glass, EV; Krege, JH; Mauck, KF; Recknor, C; Wermers, RA; Xie, L | 1 |
| Howard, E; Tagliarino-Jones, H | 1 |
| Gorai, I; Hori, H | 1 |
| Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P | 3 |
| Glendenning, P; Inderjeeth, CA; Lee, S | 1 |
| Burr, DB; Diab, T; Guldberg, RE; Reinwald, S; Wang, J | 1 |
| Eastell, R; Krege, JH; Ni, X; Rogers, A | 1 |
| Giner, M; Miranda, C; Montoya, MJ; Pérez-Cano, R; Rios, MJ; Vázquez, MA | 1 |
| Desouky, B; Ellakwa, H; Sanad, Z | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
| Boskey, AL; Calton, EF; Macleay, J | 1 |
| Landfeldt, E; Lang, A; Robbins, S; Ström, O | 1 |
| Hsieh, CF; Huang, WF; Lu, PY; Tsai, YW | 1 |
| Gitlin, M; Jick, S; Li, L; Roddam, A; Shearer, A; Shepherd, S; Taylor, A | 1 |
| Jouyama, K; Matoba, K; Mokuda, S; Okuda, Y; Onishi, M; Sawada, N; Takasugi, K; Yamada, A | 1 |
| Alonso-Garcia, G; Fernández-García, D; Mezquita-Raya, P; Muñoz-Torres, M; Reyes-García, R; Rozas-Moreno, P; Sebastián-Ochoa, A | 1 |
| Vestergaard, P | 1 |
| Bauer, DC; Schousboe, JT | 1 |
| Endo, Y; Furuya, K; Ishige, H; Kuzutani, K; Makino, A; Morikyu, T; Ohyabu, Y; Yamamoto, N | 1 |
| Chen, CH; Chen, JC; Cheng, YM; Fu, YC; Hsieh, CH; Huang, HT; Huang, PJ; Kang, L; Lin, SY | 1 |
| Cosman, F; Keaveny, TM; Kopperdahl, D; Krege, JH; Krohn, KD; Wan, X; Wermers, RA | 1 |
| Andersson, M; Halvarsson, M; Harmankaya, N; Igawa, K; Karlsson, J; Palmquist, A; Tengvall, P | 1 |
| Burge, R; Chu, BC; Curkendall, S; Diakun, DR; Foster, SA; Krege, JH; Shi, N; Stock, J | 1 |
| Abrahamsen, B; Grove, EL; Vestergaard, P | 1 |
| Chen, SH; Cheng, TT; Hsu, CY; Su, BY; Yang, TS; Yu, SF | 1 |
| Gallagher, JC; Tella, SH | 1 |
| Akbaba, G; Ates Tutuncu, Y; Berker, D; Guler, S; Isik, S; Ozuguz, U | 1 |
| Lin, SJ; Lin, TC; Yang, CY; Yang, YH | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Diab, DL; Watts, NB | 1 |
| Kao Yang, YH; Lin, SJ; Lin, TC; Yang, CY | 1 |
| Lee, CH; Lin, SJ; Lin, TC; Yang, CY; Yang, YH | 1 |
| Fahrleitner-Pammer, A; Haschka, J; Kapiotis, S; Kocijan, R; Muschitz, C; Pavo, I; Resch, H; Schima, W | 1 |
| Amugongo, SK; Dai, W; Dave, NK; Jia, J; Jiang, L; Lane, NE; Lay, YA; Li, CS; Olivera, D; Panganiban, B; Ritchie, RO; Walsh, D; Yao, W | 1 |
| Chien, JY; Chiu, WY; Juang, JM; Lee, JJ; Tsai, KS; Yang, WS | 1 |
| Amugongo, SK; Dai, W; Dave, N; Harvey, D; Jia, J; Jiang, L; Kimmel, DB; Lane, NE; Lay, YA; Ritchie, RO; Schaible, E; Yao, W; Zimmermann, EA | 1 |
| Reid, IR | 1 |
| Faverani, LP; Garcia, IR; Okamoto, R; Prado, FB; Ramalho-Ferreira, G | 1 |
| Faverani, LP; Grossi-Oliveira, GA; Okamoto, R; Okamoto, T; Ramalho-Ferreira, G | 1 |
| Connolly, JG; Gagne, JJ | 1 |
| de Oliveira Puttini, I; Faverani, LP; Luvizuto, ER; Momesso, GAC; Okamoto, R; Ramalho-Ferreira, G | 1 |
| Isaka, Y; Kida, Y; Kimura, S; Marumo, K; Saito, M; Seki, A | 1 |
| Fujiwara, S; Nakamura, M; Oda, E; Tanaka, S; Yamamoto, T | 1 |
| Faverani, LP; Freire, AR; Gruber, R; Hassumi, JS; Luvizuto, ER; Momesso, GAC; Okamoto, R; Polo, TOB; Prado, FB; Ramalho-Ferreira, G; Rossi, AC | 1 |
| Allen, MR; Aref, M; Brown, DM; Burr, DB; Hammond, M; Hutchins, GD; Jang, T; Jiang, L; Lin, C; McCarthy, BP; McGowan, B; McNerny, E; Newman, CL; Organ, JM; Persohn, S; Riley, AA; Territo, PR; Wallace, JM | 1 |
| Bettencourt, A; Martin, V | 1 |
| Baidya, S; Barron, R; Fujiwara, S; Hamaya, E; Miyauchi, A; Nicholls, RJ; Pinto, L; Takada, J; Weston, A | 1 |
| Chien, JY; Chiu, WY; Lee, JJ; Tsai, KS; Yang, WS | 1 |
| Cho, DC; Gupta, R; Han, I; Kim, CH; Kim, KT; Kwon, JT; Lee, YS; Park, EK; Seo, YJ; Seu, SY; Sung, JK | 1 |
| Fervers, F; Henrich, D; Kontradowitz, K; Leiblein, M; Marzi, I; Seebach, C | 1 |
| Amugongo, SK; Donnelly, E; Johnson, ML; Kimmel, DB; Lane, NE; Taylor, EA; Yao, X | 1 |
| Duke, J; Hripcsak, G; Huser, V; Jin, P; Kim, Y; Lambert, CG; Madigan, D; Park, H; Park, RW; Reich, C; Rijnbeek, PR; Ryan, PB; Schuemie, MJ; Shah, NH; Suchard, MA; Tian, Y; Van Zandt, M; Vashisht, R; Wu, Y; Yang, J; You, SC | 1 |
| Chen, CY; Hwang, SJ; Lee, TC; Lin, MY; Lin, SJ; Lin, YC | 1 |
| Cherubini, K; de Figueiredo, MAZ; Koth, VS; Salum, FG | 1 |
| Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z | 1 |
| Esmaily, H; Mehrnaz Aghili, S; Saeidi, S; Sahebari, M; Salari, M; Sarafraz Yazdi, M | 1 |
| Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M | 1 |
| Chen, CH; Chen, WJ; Chen, YM; Chien, LN; Ku, CK; Li, CY; Lin, SY | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
46 review(s) available for alendronate and raloxifene hydrochloride
| Article | Year |
|---|---|
Ultrasound and alendronate: new tools for osteoporosis screening and treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcium; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Prognosis; Raloxifene Hydrochloride; Treatment Outcome; Ultrasonography; Vitamin D | 1998 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Vitamin D | 1999 |
Osteoporosis: diagnosis, prevention, and treatment of established disease.
Topics: Age Factors; Aged; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Dietary Supplements; Drug Therapy, Combination; Estrogens; Etidronic Acid; Exercise; Female; Hormone Replacement Therapy; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D | 1999 |
Osteoporosis prevention and treatment.
Topics: Alendronate; Anabolic Agents; Bone Density; Calcitriol; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome; Vitamin D | 2000 |
Prevention and treatment of osteoporosis in women with breast cancer.
Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Ovary; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Osteoporosis: evaluation and treatment.
Topics: Aged; Alendronate; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Life Style; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2000 |
[Drug treatment for the treatment of primary osteoporosis].
Topics: Alendronate; Fluorides; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2000 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Osteoporosis, Postmenopausal; Postmenopause; Radiography; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Injuries; Spine | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2000 |
[Therapeutic strategies for osteoporosis].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Nutritional Physiological Phenomena; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D | 2000 |
Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Estrogen Replacement Therapy; Female; Gastrointestinal Diseases; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors | 2001 |
Osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcitonin; Calcium; Estrogen Replacement Therapy; Female; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Patient Selection; Primary Prevention; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2001 |
[Advancement of treatment for osteoporosis].
Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Osteoporosis; Raloxifene Hydrochloride; Vitamin K 2 | 2002 |
[Comparative analyses on osteoporosis guidelines in Japan, EU and USA].
Topics: Alendronate; Calcitonin; Clinical Trials as Topic; Drug Approval; Estriol; Etidronic Acid; Europe; Humans; Isoflavones; Japan; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; United States; Vitamin K 2 | 2002 |
[Osteoporosis: prevention of bone loss and fractures].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, Differential; Exercise; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Time Factors; Tomography, X-Ray Computed | 2002 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid | 2002 |
[Rehabilitation in osteoporosis].
Topics: Alendronate; Ergonomics; Exercise Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Pain; Physical Therapy Modalities; Psychotherapy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spine | 2003 |
Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors | 2003 |
An approach to postmenopausal osteoporosis treatment: a case study review.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise Therapy; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D | 2003 |
Osteoporosis management in the new millennium.
Topics: Alendronate; Bone Density; Calcitonin; Calcium; Estrogens; Etidronic Acid; Exercise; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2003 |
Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Remodeling; Bone Resorption; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2004 |
Treating osteoporosis in post-menopausal women: a case approach.
Topics: Aged; Alendronate; Densitometry; Diphosphonates; Etidronic Acid; Female; Humans; Mass Screening; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2004 |
[Who are the candidates for the treatment by raloxifen ?].
Topics: Age Factors; Alendronate; Bone and Bones; Bone Density; Diet Therapy; Drug Therapy, Combination; Exercise Therapy; Female; Fractures, Bone; Humans; Motor Activity; Osteoporosis, Postmenopausal; Parathyroid Hormone; Patient Selection; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide | 2005 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency | 2005 |
The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options.
Topics: Alendronate; Bone Density; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Teriparatide | 2006 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Long-term experience with alendronate in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid | 2006 |
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Female; Femoral Fractures; Follow-Up Studies; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Tablets; Teriparatide; Thiophenes; Time Factors | 2006 |
[Progress in diagnosis and therapy: Hypercalcemia due to primary hyperparathyroidism].
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Calcium; Diagnosis, Differential; Diagnostic Imaging; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Parathyroid Hormone; Parathyroidectomy; Polymorphism, Genetic; Raloxifene Hydrochloride; Receptors, Calcium-Sensing; Selective Estrogen Receptor Modulators; Vitamin D | 2007 |
[Recent topics in the treatment of osteoporosis in Japan].
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Osteoporosis; Raloxifene Hydrochloride | 2007 |
[Combination therapy for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin K 2 | 2007 |
[Bone quality].
Topics: Absorptiometry, Photon; Alendronate; Bone and Bones; Bone Density Conservation Agents; Clinical Trials as Topic; Diagnostic Imaging; Diphosphonates; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment | 2009 |
[Effects of SERMs on bone health. Combination therapy with raloxifene].
Topics: Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2010 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2011 |
Fracture prevention in postmenopausal women.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Calcium, Dietary; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Incidence; Postmenopause; Raloxifene Hydrochloride | 2011 |
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Monitoring, Physiologic; Osteoporotic Fractures; Raloxifene Hydrochloride; Wound Healing; Zoledronic Acid | 2012 |
Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?
Topics: Alendronate; Bone Density Conservation Agents; Calcitriol; Calcium, Dietary; Diphosphonates; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2013 |
Postmenopausal osteoporosis.
Topics: Accidental Falls; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium; Denosumab; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Risk Reduction Behavior; Teriparatide; Vitamin D; Zoledronic Acid | 2013 |
Bone regeneration: Biomaterials as local delivery systems with improved osteoinductive properties.
Topics: Alendronate; Anti-Bacterial Agents; Biocompatible Materials; Blood Platelets; Bone and Bones; Bone Regeneration; Drug Carriers; Humans; Intercellular Signaling Peptides and Proteins; Raloxifene Hydrochloride; Simvastatin | 2018 |
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D | 2020 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2023 |
25 trial(s) available for alendronate and raloxifene hydrochloride
| Article | Year |
|---|---|
Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Female; Humans; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Time Factors | 2000 |
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Collagen; Collagen Type I; Double-Blind Method; Drug Synergism; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2002 |
Compliance of osteoporotic patients with different treatment regimens.
Topics: Aged; Alendronate; Attitude to Health; Comorbidity; Female; Humans; Israel; Logistic Models; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2003 |
Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
Topics: Aged; Alendronate; Female; Humans; Logistic Models; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spain | 2004 |
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorption; Double-Blind Method; Female; Hip; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Time Factors; Treatment Outcome | 2004 |
Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Collagen; Collagen Type I; Drug Interactions; Female; Hip; Humans; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Radiography; Raloxifene Hydrochloride; Teriparatide | 2004 |
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Combinations; Drug Therapy, Combination; Estrogens, Conjugated (USP); Female; Genotype; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Receptors, Calcitriol; Selective Estrogen Receptor Modulators; Treatment Outcome | 2005 |
Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Femur Neck; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Treatment Outcome | 2005 |
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride | 2006 |
The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
Topics: Alendronate; Autonomic Nervous System; Bone Density Conservation Agents; Female; Heart; Heart Rate; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2006 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Safety | 2007 |
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Surveys and Questionnaires | 2007 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Raloxifene Hydrochloride; Risedronic Acid; Uric Acid | 2007 |
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Estrogen Replacement Therapy; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride | 2008 |
Cognitive effects of short-term use of raloxifene: a randomized clinical trial.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cognition; Educational Status; Female; Humans; Middle Aged; Neuropsychological Tests; Osteoporosis; Postmenopause; Raloxifene Hydrochloride | 2007 |
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcium; Drug Combinations; Female; Humans; Hypercalcemia; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Teriparatide | 2008 |
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Humans; Lipid Metabolism; Osteoporosis; Phosphorus; Raloxifene Hydrochloride; Spine | 2008 |
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Chelating Agents; Collagen Type I; Edetic Acid; Etidronic Acid; Female; Humans; Hypocalcemia; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Risedronic Acid | 2009 |
Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Drug Administration Schedule; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome; United States; Vitamin D | 2009 |
Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Premenopause; Procollagen; Raloxifene Hydrochloride; Reference Values; Treatment Outcome | 2011 |
Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Cholesterol, HDL; Collagen Type I; Drug Administration Schedule; Drug Monitoring; Female; Femur Neck; Humans; Lipid Metabolism; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Raloxifene Hydrochloride; Treatment Outcome | 2011 |
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Finite Element Analysis; Hip; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spine; Teriparatide; Tomography, X-Ray Computed | 2013 |
Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Humans; Hyperparathyroidism, Primary; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2013 |
Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Teriparatide; Time Factors; Treatment Outcome | 2014 |
Efficacy of Raloxifene as Add-on Therapy on Disease Activity of Postmenopausal Women with Rheumatoid Arthritis: A Double-blind, Randomized, Placebo-controlled Clinical Trial.
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride | 2023 |
102 other study(ies) available for alendronate and raloxifene hydrochloride
| Article | Year |
|---|---|
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Organ Size; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1996 |
Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Estrogens; Female; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Uterus | 1996 |
Biological basis of anti-resorptive therapies for osteoporosis.
Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Role of novel antiresorptive agents for the prevention and treatment of osteoporosis.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a
Topics: Alendronate; Colonic Diseases, Functional; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Life Expectancy; Lipids; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Sensitivity and Specificity | 1999 |
Osteoporosis: protecting bone mass with fundamentals and drug therapy.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium; Decision Trees; Dietary Supplements; Estrogen Replacement Therapy; Estrogens; Exercise; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Risk Factors; Smoking Cessation; Vitamin D | 1999 |
Biochemical bone markers.
Topics: Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Lipids; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1999 |
Frequency of bone densitometry for osteoporosis?
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Time Factors | 1999 |
New ways to manage the old problem of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Diagnosis, Differential; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 1999 |
Vertebroplasty: an opportunity to do something really good for patients.
Topics: Alendronate; Bone Cements; Calcitonin; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2000 |
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
Topics: Aged; Alendronate; Bone and Bones; Bone Demineralization, Pathologic; Estrogen Antagonists; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk | 2000 |
Alendronic acid in primary prevention: new indication. No reduction in fracture risk.
Topics: Alendronate; Clinical Trials as Topic; Cost-Benefit Analysis; Esophagitis; Estrogen Replacement Therapy; Female; Fractures, Bone; France; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2000 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Densitometry; Dose-Response Relationship, Drug; Estrogens; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Vitamin D | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagonists; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures | 2000 |
Managing menopause after breast cancer: balancing risks and benefits.
Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcitonin; Climacteric; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Heart Diseases; Humans; Menopause; Menopause, Premature; Neoplasm Recurrence, Local; Osteoporosis; Pregnancy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2001 |
Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Data Interpretation, Statistical; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2001 |
Medication update.
Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Dosage Forms; Drug Interactions; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators | 2001 |
The role of serial bone mineral density testing for osteoporosis.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Female; Hormone Replacement Therapy; Humans; Osteoporosis, Postmenopausal; Predictive Value of Tests; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Humans; National Health Programs; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures | 2001 |
For osteoporosis, are two antiresorptive drugs better than one?
Topics: Alendronate; Drug Therapy, Combination; Humans; Osteoporosis; Raloxifene Hydrochloride | 2002 |
A 60-year-old woman trying to discontinue hormone replacement therapy.
Topics: Alendronate; Breast Neoplasms; Contraindications; Coronary Disease; Decision Making; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fibrocystic Breast Disease; Hot Flashes; Humans; Hysterectomy; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis | 2002 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibility; Humans; Osteoporosis; Physician's Role; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2001 |
Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats.
Topics: Alendronate; Animals; Estrogens; Female; Fracture Healing; Fractures, Bone; Ovariectomy; Radiography; Raloxifene Hydrochloride; Rats | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Disabled Persons; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pain; Raloxifene Hydrochloride; Risedronic Acid; Sex Factors; Spinal Fractures | 2002 |
Medications for postmenopausal osteoporosis prevention.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators | 2002 |
Hip fracture patients are not treated for osteoporosis: a call to action.
Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Calcium; Estrogen Antagonists; Estrogens; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Treatment Failure; Vitamin D | 2002 |
New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Drug Administration Schedule; Ethinyl Estradiol; Female; Femur; Osteogenesis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Spine; Tensile Strength; Teriparatide; Tibia; Time Factors | 2003 |
Early discontinuation of treatment for osteoporosis.
Topics: Alendronate; Bone Diseases, Metabolic; Breast Neoplasms; California; Cohort Studies; Estrogen Replacement Therapy; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Interviews as Topic; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Treatment Refusal | 2003 |
[Osteoporosis therapy compared. More solid bones with bisphosphonates].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors | 2003 |
[Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
Topics: Age Factors; Aged; Alendronate; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors | 2003 |
[Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach].
Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium; Cost-Benefit Analysis; Diphosphonates; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Vitamin D | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures | 2004 |
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid; Female; Germany; Hip Fractures; Humans; Incidence; Insurance, Pharmaceutical Services; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2004 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Health Surveys; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures; Vitamin D | 2004 |
New help for old bones.
Topics: Age Distribution; Aged; Alendronate; Calcitonin; Estrogen Replacement Therapy; Humans; Mass Screening; Nurse's Role; Osteoporosis; Patient Education as Topic; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; United States | 2005 |
Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.
Topics: Alendronate; Animals; Bone Density; Computational Biology; Estrogens; Female; Femur; Gene Expression Profiling; Gene Expression Regulation; Osteogenesis; Ovariectomy; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley | 2005 |
[New therapeutic approaches to osteoporosis].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride | 2006 |
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Male; Managed Care Programs; Middle Aged; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Decision Support Techniques; Etidronic Acid; Female; Humans; Markov Chains; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Italy; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Factors; Vitamin D | 2006 |
Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Dogs; Etidronic Acid; Female; Osteoblasts; Periosteum; Raloxifene Hydrochloride; Ribs; Risedronic Acid | 2006 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Cross-Over Studies; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Patient Compliance; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States | 2007 |
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Risk; Thromboembolism | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
Topics: Alendronate; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Patient Compliance; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Risedronic Acid | 2007 |
Modern milk alkali syndrome--a preventable serious condition.
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Diuretics; Female; Fluid Therapy; Furosemide; Humans; Hypercalcemia; Middle Aged; Raloxifene Hydrochloride; Treatment Outcome | 2007 |
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Epidemiologic Methods; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride | 2008 |
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.
Topics: Alendronate; Amino Acids; Animals; Arginine; Bone Density Conservation Agents; Bone Remodeling; Collagen; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Lumbar Vertebrae; Lysine; Raloxifene Hydrochloride; Risedronic Acid | 2008 |
[Long term effects of raloxifen on the bones].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Time Factors; Treatment Outcome | 2008 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Italy; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Treatment Failure | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Drug Prescriptions; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Patient Compliance; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Sex Distribution; Spinal Fractures; Treatment Outcome | 2009 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Confounding Factors, Epidemiologic; Dietary Supplements; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2009 |
Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Female; Genistein; Osteoporosis; Ovariectomy; Phytoestrogens; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Teriparatide; Treatment Outcome | 2008 |
FPIN's clinical inquiries. Combination therapy for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride | 2010 |
Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Topics: Aged; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation Agents; Cohort Studies; Comorbidity; Confounding Factors, Epidemiologic; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Pulmonary Disease, Chronic Obstructive; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2010 |
Stroke in relation to use of raloxifene and other drugs against osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment; Stroke | 2011 |
Effects of the combination treatment of raloxifene and alendronate on the biomechanical properties of vertebral bone.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Densitometry; Drug Therapy, Combination; Humans; Lumbar Vertebrae; Models, Statistical; Osteoporosis; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley | 2011 |
Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Cells, Cultured; Estradiol; Female; Humans; Male; Middle Aged; Osteoarthritis; Osteoblasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Raloxifene Hydrochloride; RANK Ligand; RNA, Messenger | 2011 |
Fourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep.
Topics: Alendronate; Animals; Bone and Bones; Bone Diseases, Metabolic; Raloxifene Hydrochloride; Sheep; Spectroscopy, Fourier Transform Infrared | 2011 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Registries; Retrospective Studies; Risedronic Acid; Sweden; Thiophenes | 2011 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Case-Control Studies; Cohort Studies; Denmark; Diabetes Complications; Diphosphonates; Drug Therapy; Etidronic Acid; Female; Humans; Jaw Diseases; Male; Neoplasms; Organometallic Compounds; Osteitis; Osteomyelitis; Osteoporosis; Parathyroid Hormone; Periostitis; Radiotherapy; Raloxifene Hydrochloride; Risk Factors; Sjogren's Syndrome; Strontium; Thiophenes | 2012 |
Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Osteoporosis; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risk; Taiwan | 2011 |
Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Female; General Practice; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Raloxifene Hydrochloride; Thiophenes; Time Factors; United Kingdom | 2012 |
Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Glucocorticoids; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Severity of Illness Index; Vitamin K Deficiency | 2012 |
Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
Topics: Adiponectin; Aged; Alendronate; Body Mass Index; Bone Density; Bone Density Conservation Agents; Female; Humans; Leptin; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride | 2012 |
Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
Topics: Aged; Alendronate; Atherosclerosis; Bone Density Conservation Agents; Calcium; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Myocardial Infarction; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies | 2012 |
The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats.
Topics: Alendronate; Androgens; Animals; Benzofurans; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Interactions; Female; Male; Parathyroid Hormone; Quinolines; Rabbits; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Steroid; Selective Estrogen Receptor Modulators; Teriparatide | 2012 |
Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Stress; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Teriparatide | 2012 |
Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone.
Topics: Adhesiveness; Alendronate; Animals; Bone Density Conservation Agents; Bone Screws; Drug Implants; Friction; Materials Testing; Osseointegration; Porosity; Raloxifene Hydrochloride; Rats; Tibia; Titanium; Treatment Outcome | 2013 |
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; United States; Women's Health | 2013 |
Heart failure in patients treated with bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Heart Failure; Humans; Male; Middle Aged; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2013 |
Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Female; Humans; Male; Medication Adherence; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Young Adult | 2013 |
Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Case-Control Studies; Cohort Studies; Databases, Factual; Female; Follow-Up Studies; Humans; Incidence; Medication Adherence; Middle Aged; National Health Programs; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Secondary Prevention; Taiwan | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Calcitonin; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; Risk Assessment; Taiwan | 2014 |
Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Female; Humans; Incidence; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; Risk; Taiwan; Venous Thromboembolism | 2014 |
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Femur; Hormone Replacement Therapy; Lumbar Vertebrae; Osteoporosis; Osteoporotic Fractures; Ovariectomy; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Weight-Bearing; X-Ray Microtomography | 2014 |
The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Female; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Taiwan | 2014 |
Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.
Topics: Alendronate; Animals; Bone Density; Female; Ovariectomy; Raloxifene Hydrochloride; Rats; Tibia | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Raloxifene enhances peri-implant bone healing in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Dental Implants; Female; Implants, Experimental; Microscopy, Confocal; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tibia | 2015 |
Alveolar bone dynamics in osteoporotic rats treated with raloxifene or alendronate: confocal microscopy analysis.
Topics: Alendronate; Alveolar Process; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; Microscopy, Confocal; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2015 |
Comparison of Calipers for Matching on the Disease Risk Score.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Computer Simulation; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Ezetimibe; Female; Gastrointestinal Hemorrhage; Humans; Male; Medicare; Models, Theoretical; Monte Carlo Method; Odds Ratio; Osteoporotic Fractures; Prognosis; Propensity Score; Raloxifene Hydrochloride; Risk Assessment; Simvastatin; United States | 2016 |
Effect of antiresorptive drugs in the alveolar bone healing. A histometric and immunohistochemical study in ovariectomized rats.
Topics: Alendronate; Alveolar Process; Animals; Bone Density Conservation Agents; Female; Immunohistochemistry; Osteocalcin; Osteogenesis; Osteoprotegerin; Ovariectomy; Raloxifene Hydrochloride; RANK Ligand; Rats; Rats, Wistar; Tartrate-Resistant Acid Phosphatase; Wound Healing | 2017 |
Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.
Topics: Alendronate; Animals; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Collagen; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Femur; Glycation End Products, Advanced; Ovariectomy; Rabbits; Raloxifene Hydrochloride; Stress, Mechanical; Teriparatide; Weight-Bearing | 2017 |
Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.
Topics: Aged; Alendronate; Asian People; Bone Density Conservation Agents; Databases, Factual; Female; Hospitals; Humans; Incidence; Japan; Kaplan-Meier Estimate; Middle Aged; Osteoporotic Fractures; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risk | 2018 |
Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Dental Implants; Disease Models, Animal; Female; Immunoenzyme Techniques; Implants, Experimental; Microscopy, Confocal; Osseointegration; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Tibia; X-Ray Microtomography | 2018 |
Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diaphyses; Dogs; Drug Therapy, Combination; Female; Femur; Lumbar Vertebrae; Magnetic Resonance Imaging; Models, Animal; Osteoporosis; Raloxifene Hydrochloride | 2017 |
Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Drug Utilization; Female; Humans; Incidence; Japan; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; Vitamin D | 2018 |
The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Osteoporosis; Prevalence; Raloxifene Hydrochloride; Retrospective Studies; Tooth Extraction | 2018 |
Effect of a bisphosphonate and selective estrogen receptor modulator on bone remodeling in streptozotocin-induced diabetes and ovariectomized rat model.
Topics: Alendronate; Animals; Biomarkers; Bone Density; Bone Remodeling; Collagen Type I; Diabetes Mellitus, Experimental; Diphosphonates; Disease Models, Animal; Female; Humans; Lumbar Vertebrae; Osteocalcin; Osteoporosis, Postmenopausal; Ovariectomy; Peptides; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Streptozocin; X-Ray Microtomography | 2018 |
Do antiosteoporotic drugs improve bone regeneration in vivo?
Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Blotting, Western; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Regeneration; Bony Callus; Calcium-Regulating Hormones and Agents; Collagen Type I; Female; Femur; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Macrophage Colony-Stimulating Factor; Osteocalcin; Osteogenesis; Osteogenesis, Distraction; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Rats; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Thiophenes; Tomography, X-Ray Computed | 2020 |
Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1-34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcification, Physiologic; Collagen; Cortical Bone; Estrogens; Female; Osteocytes; Ovariectomy; Raloxifene Hydrochloride; Rats, Sprague-Dawley; Teriparatide | 2020 |
Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Treatment Outcome | 2020 |
Effectiveness of antiresorptive medications in women on long-term dialysis after hip fracture: A population-based cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Follow-Up Studies; Hip Fractures; Humans; Incidence; Longitudinal Studies; Middle Aged; Prognosis; Raloxifene Hydrochloride; Renal Dialysis; Retrospective Studies; Survival Rate; Taiwan | 2020 |
Morphological and immunohistochemical features of tooth extraction sites in rats treated with alendronate, raloxifene, or strontium ranelate.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Humans; Raloxifene Hydrochloride; Rats; Rats, Wistar; Thiophenes; Tooth Extraction | 2021 |
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2022 |
Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Taiwan; Teriparatide; Zoledronic Acid | 2022 |